secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2026-02-04T23:59:59+00:00
Accession:  0001551152-26-000004
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie Q4 revenue $16.6B (+10%); FY2025 adj EPS $10.00; guides FY2026 adj EPS $14.37-$14.57
--------------------------------------------------------------------------------

- FY2025 revenue $61.160B (+8.6% reported); GAAP diluted EPS $2.36; adjusted diluted EPS $10.00 (-1.2% YoY).
- Q4 revenue $16.618B (+10% reported); GAAP EPS $1.02; adjusted EPS $2.71; includes $0.71 IPR&D hit.
- Immunology portfolio grew 14% in FY2025; Skyrizi $17.562B, Rinvoq $8.304B; Humira fell to $4.540B.
- FY2026 adjusted EPS guidance $14.37-$14.57, excluding future IPR&D and milestones expense.
- Announced voluntary pricing agreement with Trump admin; $100B U.S. R&D/capex over 10 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000155115226000004/0001551152-26-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000155115226000004/abbv-20260204.htm
  HTML page:      https://secwatch.observer/filing/0001551152-26-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer